NY-MORROW-SODALI
Morrow Sodali announced today that Debt Capital Markets industry experts Damian Watkin, Damir Hadžiosmanović, Ken Abela and Tina Siu, have joined the firm as part of a global strategy to strengthen its bonds-related services offering.
The team, which provides 50+ years of combined experience working on over 800 debt-related deals, joins Morrow Sodali from D.F. King and will be based in London and Hong Kong, bolstering the firm’s global presence in Debt Services. They will work alongside leading in-house expert Pia Gowland who from now on will oversee Morrow Sodali’s Debt Services activities in the Americas.
Damian Watkin, who joins Morrow Sodali as a Senior Director in the firm’s London office, brings 20 years’ experience in the capital markets industry working with global financial institutions, corporate and sovereign issuers, with extensive expertise in executing liability management and debt restructuring transactions and researching ownership in capital structures. In his previous role at D.F. King, Mr. Watkin built and led the firm’s bonds business outside of the US market, working with a broad range of debt issuers, and their advisors, in some of the largest or highest profile transactions of recent years.
“We are very excited to join the entrepreneurial and client-focused team at Morrow Sodali and be able to offer a seamless service from a truly global and technology-led execution platform to bond issuers and their advisers,” said Mr. Watkin. “Morrow Sodali now has a global footprint, with experienced execution professionals based in Asia, Europe and the Americas.”
Joining Mr. Watkin in London as a Director, Damir Hadžiosmanović has nearly 20 years’ experience in working with corporate and sovereign issuers, assisting them in executing various liability management transactions and bondholder identifications, as well as debt restructurings and schemes of arrangement.
Ken Abela, who joins Morrow Sodali as a Director, brings nearly 20 years’ experience, of which 17 years in Asia, in assisting corporate and sovereign issuers in executing liability management and debt restructuring transactions. Mr. Abela will be based in Hong Kong and will be responsible for strengthening the firm’s Debt Services offering across Asia Pacific markets.
“We are looking forward to expanding Morrow Sodali’s debt-related services in Asia, providing bond issuers and their advisors in the region with an experienced local point of contact, with the ability to assist with transactions and provide advice to practitioners in their own time zone,” said Mr. Abela.
Joining Mr. Abela in Hong Kong, Tina Siu has assisted in providing D.F. King’s debt-related activities led by Mr. Abela, with a strong track record of supporting bond issuers in executing liability management transactions across Asian markets. Prior to D.F. King, Ms. Siu worked with financial institutions focusing on debt market research as well as conducting financial analysis for corporate clients.
Morrow Sodali Global Corporate Director Giulio Pediconi commented: “We are delighted to welcome such an experienced team within the Morrow Sodali family. With the global expansion of corporate debt markets, our combined expertise across our dedicated hubs in New York, London and Hong Kong will enable us to expand our services and offer our clients a truly global coverage in this key market.”
About Morrow Sodali
Morrow Sodali is a leading provider of strategic advice and shareholder and bondholder services to corporate and sovereign clients around the world. The firm provides corporate boards and executives with strategic advice and services relating to corporate governance, shareholder and bondholder communication and engagement, capital markets intelligence, proxy solicitation, shareholder activism, mergers and acquisitions and debt-related transactions.
From headquarters in New York and London, and offices and partners in major capital markets, Morrow Sodali serves more than 700 corporate clients in 40 countries, including many of the world’s largest multinational corporations. In addition to listed and private companies, its clients include mutual funds, ETFs, stock exchanges and membership associations.
For further information about Morrow Sodali, please visit www.morrowsodali.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005017/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press release
A R$490 million investment expands the supply of raw material used in the production of absorbent items Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom